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Peroxisome proliferators activated receptor-gamma2 (PPARγ2) represents the transcriptional master regulator of adipocyte
diﬀerentiation and therefore has been suggested as a candidate gene for obesity, insulin resistance, and dyslipidemia. The objective
of the study was to investigate for the ﬁrst time the potential association of the most common variant Pro12Ala (p.P12A)
substitutionofthePPARγ2genewithbodymassindex(BMI),bloodpressure,fastingplasmaglucose,plasmatotalcholesterol,LDL
andHDLcholesterol,andplasmatriglycerideinasampleof202(138femalesand64male)type2diabeticPalestinians.Genotyping
of the PPARγ2 p.P12A polymorphism was determined by polymerase chain reaction-restriction fragment length polymorphism
(PCR-RFLP) analysis. The A12 allele was associated with lower fasting plasma glucose (P = .03) but had no inﬂuence on blood
pressure, BMI, or other metabolic parameters. In obese patients, the p.P12A substitution was associated with elevated total plasma
cholesterol levels (P = .02) and a tendency toward increased LDL cholesterol level (P = .06). In conclusion, the p.P12A variant of
the PPARγ2 may inﬂuence cardiovascular risk through eﬀects on lipid metabolism in obese T2D Palestinian patients.
Copyright © 2009 S. Ereqat et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Type 2 diabetes mellitus (T2DM) showed to be a cocktail
of genetic discovery as described by Freeman and Cox
[1]. T2DM cases would have inborn with a diversity of
diﬀerent genetic factors that together with environmental
factors combine as the primary cause and contributed to the
disease.
Studies enlightening the epidemiology of diabetes mel-
litus among Palestinians are scarce. A Palestinian study
conducted at 2001 [2] showed DM prevalence in 12% of
urbanPalestinianpopulation including 492menandwomen
30–65 years old. According to the WHO global estimate,
and the epidemic nature of diabetes; prevalence of diabetes
is expected to increase in Palestine and numbers should
be revised to have more realistic estimation, which enables
healthproviderstobeawareofthediseasemagnitude,sothat
more eﬀective health strategies can be adopted.
Preoxisome proliferator-activated receptor gamma
(PPARγ) is a nuclear hormone receptor which plays a
critical role in regulating adipocyte diﬀerentiation and the
transcription of genes that are important for lipogenesis.
In macrophages, the activated PPARγ promotes the cellular
eﬄux of phospholipids and cholesterol in the form of high
density lipoprotein (HDL) [3, 4]. PPARγ2 is a key modulator
of adipogenesis and insulin signaling [5]. Cytosine to
guanine single nucleotide polymorphism (rs1805192)
in PPARγ2 gene (NM 015869) resulting in a proline to
alanine substitution at codon 12, which has been found to
modulate the transcriptional activity of the gene [6], and
associated with altered insulin sensitivity [7]. Although most
studies have shown a statistically signiﬁcant T2DM risk
reduction given by Ala variant [8–11], some others have
not [12–15], suggesting variability in the contribution of
this variant to the risk of T2DM. In a previous study of 333
Palestinian subjects (n = 219 T2DM patients and n = 1142 PPAR Research
Table 1: Anthropometrical and biochemical parameters of the study groups. Data are in means ± SD. BMI =Body mass index; SBP=systolic
blood pressure; DBP=diastolic blood pressure; TC: total cholesterol; TG: Triglyceride; FPG: fasting plasma glucose; NS: not signiﬁcant; D:
Diet; I: insulin; IO: Insulin and oral hypoglycemic agent; O: oral hypoglycemic agent.
Parameters Obese subjects Nonobese subjects P
n = 121 n = 81
Sex (M/F) 31/90 33/48
Age (years) 58.6+1 0 .15 9 .9+1 0 .1N S
Age at diagnosis 49.8+1 0 .14 9 .6+1 0 .5N S
BMI (kg/m2)3 5 .4+4 .92 5 .8+2 .5 <.001
SBP (mmHg) 126.1+1 8 .8 130.1+1 9 .0N S
DBP (mmHg) 78.6+9 .37 9 .6+1 4 .8N S
FPG (mg/dL) 208.4+8 4 .0 211.3+8 0 .3N S
TC (mg/dL) 201.5+5 2 .6 189.6+4 4 .3N S
TG (mg/dL) 181.4+7 8 .9 167.5+8 3 .5N S
HDL (mg/dL) 43.6+1 6 .04 1 .3+1 3 .4N S
LDL (mg/dL) 120.1+4 8 .5 109.6+4 4 .9N S
Therapy(n) D/I/IO/O 4/22/16/79 2/22/5/52 NS
normoglycemic controls), we were unable to demonstrate a
signiﬁcant association between the p.P12A variant and the
T2DM among Palestinians (0.055 versus 0.048, OR = 0.87,
P = .9) (unpublished data). The aim of this study was to
investigate for the ﬁrst time the relationship between p.P12A
polymorphism of PPARγ2 gene and blood pressure, BMI
and other related metabolic parameters in type 2 diabetic
Palestinians.
2.SubjectsandMethods
After an institutional review board approval and a com-
pletion of an informed consent, two hundred and two
(202) diabetic type 2 patient volunteers (121 obese subjects
(BMI ≥ 30kg/m2) and 81 nonobese subjects (BMI <
30kg/m2) were randomly recruited on the basis of routine
visits to the Amari Refugee camp outpatient UNRWA
clinic in the Ramallah District, 14km north Jerusalem.
The study protocol and the consent form were approved
by the institutional Human Research Ethics Committee at
Al-Quds University. The volunteers were unrelated, over
40 years old and diagnosed with diabetes according to
WHO criteria or currently being treated with medication for
diabetes. Subjects with previous diagnosis of type 1 diabetes
were excluded from the study. Complete medical records
including family history for diabetes, resting blood pressure,
and anthropometric parameters: weight, height, and BMI
(weight in kilograms divided by the square of height in
meters) were obtained.
For laboratory analysis, 5mL of blood were obtained
after overnight fast. Blood samples were collected in EDTA-
tubes and immediately centrifuged at room tempera-
ture. Plasma was aliquoted for glucose, cholesterol, HDL-
cholesterol, and triglyceride determination. Plasma glucose
was determined by a glucose oxidase method. Plasma
total cholesterol, triglyceride and HDL cholesterol were
determined by enzymatic methods using commercial kits
(Human, Wiesbaden, Germany). Plasma LDL cholesterol
was calculated by the Friedewald formula [16]. All the
biochemical measures were obtained in milligram/deciliter
(mg/dL), to convert plasma glucose, triglyceride, and choles-
terol values into millimolar concentration (mmol/L). Multi-
ply the given values in (mg/dL) units by 0.0555, 0.0113, and
0.0259, respectively.
Genomic DNA was extracted from peripheral blood
according to standard procedures (Epicenter, Madison, Wis,
USA). The p.P12A polymorphism was detected by PCR-
RFLP analysis as previously described by Johansen et al. [17]
with the following modiﬁcations: The PCR reactions were
carried out using 100ng of puriﬁed genomic DNA samples,
with 1μM of each primer (forward/reverse) and PCR-Ready
Supreme mix (Syntezza Bioscience, Jerusalem) in a ﬁnal
volume of 25μl.
3.StatisticalAnalysis
Statisticaldiﬀerences between mean values of the continuous
variables of subjects with and without the polymorphism
were evaluated by student’s t test and conﬁrmed by a
nonparametric analysis using Mann-Whitney test. Chi-
square analysis was performed to test the allelic frequency
diﬀerences between obese and nonobese subjects. Hardy-
Weinberg equilibrium was computed to the expected geno-
type distribution. Analysis was performed using SPSS pro-
gram version 15. P value less than .05 was considered
signiﬁcant.
4. Results
The biochemical and anthropometric results for the 121
obese subjects and 81 nonobese subjects are shown in
Table 1. No signiﬁcant diﬀerences in biochemical parametersPPAR Research 3
were noted between the two groups. The genotype analysis
in nonobese subjects revealed that 73 individuals were
homozygote for the wild P12P allele, and 8 individuals
were heterozygote P12A. Among the obese group, 106
individuals were homozygote for the wild P12P allele, 14
individualswereheterozygoteP12Aandonlyonepatientwas
homozygote A12A for the rare allele. Because there was only
one homozygote patient for the rare allele, this individual
was combined with the heterozygote group and compared
with the homozygote wild group in all of the statistical
analyses. No signiﬁcant statistical correlation was observed
between medication for diabetes and either genotype or
gender (P>. 05) in both groups. The overall frequency of
the A12 allele in T2DM patients was 0.059 and it was in
Hardy-Weinberg equilibrium. Since PPARγ2 is an important
regulator of adipogenesis, it was relevant to verify if the
p.P12A variant was associated with obesity. The frequency
of the A12 allele did not diﬀer signiﬁcantly between obese
and nonobese diabetic subjects (0.066 versus 0.049, P = 0.6).
No signiﬁcant diﬀerences in the genotypic distribution were
foundbetweenthetwogroupsasshowninTable 2.Thepres-
ence of A12 variant was signiﬁcantly associated with lower
plasma glucose (174 ± 45.9 vresus 214 ± 84.9mg/dL, P =
.03) for the whole group (Table 3). However, there were
no signiﬁcant statistical diﬀerences between the PPARγ2
genotype and gender, age, BMI, plasma triglyceride, plasma
totalcholesterol,HDLandLDLcholesterol,aswellassystolic
and diastolic blood pressure.
Among obese subjects, p.P12A carriers showed signif-
icantly higher level of plasma total cholesterol (232.2 ±
41.8 versus 197.1 ± 52.7mg/dL, P = .0 2 )a n dt e n d e dw i t h
a borderline signiﬁcant to have lower plasma glucose than
those with P12P genotype (P = .05). A tendency toward
increased levels of LDL cholesterol among P12A genotype
were also observed but not signiﬁcant (P = .06) (Table 3).
Both subgroups showed no association of P12A genotype
and triglyceride, and HDL cholesterol.
5. Discussion
In this study, the frequency of the A12 allele of the PPARγ2
gene in diabetic subjects was similar to that reported for
other Arabic populations such as Qatari and Tunisian
ones [13, 14], but was slightly higher than in East Asian
(Malaysians,Chinese,andKoreans)populations[15,18]and
much lower than that reported in Caucasian subjects [19].
This might be explained by the genetic background shared
between our studied group and the other Arabic origin
subgroups [13, 14] compared with other ethnic groups [15,
18, 19]. More comprehensive genotyping studies are needed
to clarify this point. Of at most interest is to recruit and
genotype large representative Palestinian T2DM patients to
get conclusive results for comparison with the Caucasian
group.
In agreement with early published studies, we could
not demonstrate an eﬀect of the p.P12A variant on several
traits that are associated with insulin resistant syndrome,
Table 2: PPARγ2 genotype frequencies in obese and nonobese
Type 2 diabetic patients. The chi-square test was performed for
association.
Genotype (n)
P12P P12A A12 frequency
Obese 106 15 0.066
Nonobese 73 8 0.049
All subjects 179 23 0.059
such the BMI, blood pressure, and plasma triglyceride levels
[15, 20].
On the other hand, our study showed the diabetic
subjects with the P12A genotype had lower fasting plasma
glucose levels than those with the P12P genotype. This eﬀect
had a borderline signiﬁcance in the obese group. Thamer
et al. [21] indicated that the mechanism by which the A12
allele improves insulin sensitivity might involve enhanced
suppression of lipid oxidation permitting more eﬃcient
glucose disposal, however, this eﬀect should be clariﬁed in
future studies with detailed laboratory tests such as glycated
hemoglobin and insulin sensitivity measures by the gold
standard OGTT and/or the hyperinsulinemic euglycemic
clamp [22].
Of the variables tested, the P12A genotype had the
greatest eﬀect on plasma total cholesterol with an elevated
levelamongdiabeticobesethannonobesesubjectsconsistent
with early published studies in Caucasian and Japanese
populations [8, 19]. Plasma LDL cholesterol exhibited
a similar trend, but did not achieve signiﬁcance. Since
both obese and nonobese groups had similar lipid proﬁle
(Table 1). This eﬀect is not simply reﬂected by obesity, it
might be revealed due to variable interactions of the Ala
allele with other genetic and environmental factors. In the
Finnish study, the eﬀect of P12A genotype on T2DM risk
was modiﬁed by physical activity [23]. Combining all these
results together, it may suggest an intrinsic reduction in
the PPARγ2 activity; however, it was shown that the A12
substitution in the PPARγ2 gene associated with reduced
lipoprotein lipase activity [24] which results in impaired
clearance of LDL, VLDL resulting in elevated total plasma
cholesterol, LDL, and VLDL levels. In contrast, other studies
did not ﬁnd impact of p.P12A of PPARγ2 on lipid proﬁle
in diabetic and normoglycemic subjects [25]. We believe
that ethnic diﬀerences, BMI, gender, physical activities, study
design, and sample size all could be considered as reasons for
discrepancies in association studies.
In conclusion, this study is considered to be the ﬁrst to
focus on molecular type-2 diabetes on Palestinians which
will help in draw a baseline for further diabetes research
studies in Palestine. Our ﬁndings showed no signiﬁcant
impact of the p.P12A PPARγ2 polymorphism on BMI,
blood pressure and triglyceride. However, this variant in
obese T2DM patients may inﬂuence cardiovascular risk
through eﬀects on lipid metabolism. The role of other
polymorphismsparticularly—iffound—inalocationnearto
the p.P12A is still to be deﬁned in our population.4 PPAR Research
Table 3: Biochemical and anthropometrical parameters for subjects based on PPARγ2 genotype. The chi-square test was performed for
association.
All subjects Obese subjects
P12P P12A P P12P P12A P
Age (years) 58.8 ± 10.06 1 .4 ± 10.5N S5 8 .3+1 0 .46 1 .3+7 .6N S
BMI (kg/m2)3 1 .5 ± 6.23 1 .5 ±6.7N S3 5 .4+4 .93 5 .1+4 .9N S
FPG (mg/dL) 214.1 ± 84.9 174.3 ±45.9 .03 214.1 ±86.8 168.5 ±45.5. 0 5
TC (mg/dL) 192.5 ± 51.0 211.1 ±50.2 NS 197.1 ±52.7 232.2 ±41.8. 0 2
TG (mg/dL) 176.1 ± 82.2 173.6 ±71.3 NS 181.9 ±79.0 177.0 ±80.6N S
HDL (mg/dL) 42.5 ± 15.34 3 .6 ±13.5N S4 3 .9 ±16.24 1 .8 ±15.1N S
LDL (mg/dL) 114.8 ± 47.7 124.2 ±43.7 NS 117.0 ±49.3 141.9 ±37.4. 0 6
SBP (mmHg) 127.5 ± 18.5 129.4 ±22.3 NS 125.7+1 8 .6 128.4+2 0 .6N S
DBP (mmHg) 78.7 ± 11.68 1 .0 ±11.0N S 7 8 .0+8 .98 2 .8+1 1 .1N S
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